Treatment Standards for Blood Clots in APS

Once you have experienced a blood clot (thrombosis) and been diagnosed with Antiphospholipid Syndrome (APS), the primary goal of treatment is to prevent another clot from forming. Because APS is a chronic condition, this treatment often involves indefinite anticoagulation, particularly after an unprovoked, recurrent, or arterial clot, but the exact duration is an individualized decision ^[1][2].

The Gold Standard: Warfarin

For most patients with thrombotic APS, the “gold standard” of care is a Vitamin K Antagonist (VKA), most commonly Warfarin ^[1][3].

Unlike newer blood thinners, Warfarin has decades of research proving its effectiveness in APS. It works by interfering with how your body uses Vitamin K to make clotting factors. Because its effect can change based on your diet and other medications, it requires regular monitoring through a blood test called the INR (International Normalized Ratio) ^[2].

Understanding Your Target INR

The INR measures how much longer it takes your blood to clot compared to a person not on medication. Your doctor will set a “target range” based on your history:

• Venous APS (clots in veins, like DVT or PE): The standard target is typically an INR of 2.0 to 3.0 ^[2][4].
• Arterial APS (clots in arteries, like Stroke): Management varies. Depending on your risk factors, your doctor may target a higher range of 3.0 to 4.0, target 2.0-3.0, or add low-dose aspirin to your 2.0–3.0 regimen ^[2][5]. High-intensity warfarin adds bleeding risk, so do not adjust your INR target or add aspirin without your specialist.

DOACs in APS

In recent years, many people have switched to Direct Oral Anticoagulants (DOACs), such as Rivaroxaban (Xarelto) or Apixaban (Eliquis), because they do not require regular blood tests.

However, for high-risk APS patients, DOACs are generally avoided.
Clinical trials have shown that patients with “triple-positive” APS or a history of arterial clots (like strokes) have a significantly higher risk of experiencing another clot while on a DOAC compared to Warfarin ^[1][6]. For this reason, international guidelines strongly advise against using DOACs for triple-positive or arterial APS ^[3][7]. They may only be considered in selected, lower-risk venous APS patients after specialist discussion. Never start, stop, or change your anticoagulant without your prescriber.

Emergency Action Plan: Bleeding

Because standard APS treatment involves blood thinners, you must be alert for signs of severe bleeding. Seek emergency medical help for:

• Uncontrolled bleeding from a cut.
• Black, tarry, or bloody stools.
• Vomiting blood or material that looks like coffee grounds.
• A severe or unusual headache, neurologic symptoms, or any significant head injury or fall.

Keep your intake of Vitamin K (like leafy greens) reasonably consistent rather than avoiding it entirely. Always check all new medicines, antibiotics, supplements, and NSAIDs with your anticoagulation team.

Managing “Breakthrough” Clots and Emergencies

If a patient experiences a new clot while their INR is in the correct range, it is called a “breakthrough” event. In these cases, specialists may adjust the INR target, switch to daily injections of Low-Molecular-Weight Heparin (LMWH), or add an antiplatelet medication ^[5][2]. Acute thrombosis is generally treated initially with therapeutic heparin while Warfarin is introduced.

As discussed in previous sections, Catastrophic APS (CAPS) is a rare but critical emergency where clots form in multiple organs simultaneously ^[8]. Because CAPS moves so quickly, the treatment protocol is intensive and usually involves a “triple therapy” approach in the hospital ^[9]:

• Anticoagulation: High-dose heparin (usually delivered through an IV) to stop the clotting process ^[10].
• Corticosteroids: High-dose steroids to calm the massive inflammatory response ^[11].
• Plasma Exchange (PLEX) or IVIG: Procedures to physically remove the harmful antibodies from the blood or neutralize them with healthy donor antibodies ^[10][11].